Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Andrié, René P ^a   Becher, Ulrich M ^a   Frommold, Ricarda ^a   Tiyerili, Vedat ^a   Schrickel, Jan W ^a   Nickenig, Georg ^a   Schwab, Jörg O ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; DOBUTAMINE; INTERLEUKIN 6; NORADRENALIN; PROCALCITONIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCITONIN; CREATININE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ADULT; AGED; AORTA BALLOON; ARTICLE; CARDIOGENIC SHOCK; COUNTERPULSATION; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVASCULARIZATION; SURVIVOR; UNIVARIATE ANALYSIS; ACUTE KIDNEY FAILURE; ANALYSIS OF VARIANCE; BLOOD; COMPLICATION; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; INTENSIVE CARE UNIT; INTRAAORTIC BALLOON PUMP; KAPLAN MEIER METHOD; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SHOCK, CARDIOGENIC;

ACUTE KIDNEY INJURY; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CALCITONIN; CREATININE; FEMALE; HEMODYNAMICS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; INTRA-AORTIC BALLOON PUMPING; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; SHOCK, CARDIOGENIC;

EID: 84864805663     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11467     Document Type: Article

References (30)

1. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock; NRMI Investigators. JAMA 2005, 294:448-454. 10.1001/jama.294.4.448, 16046651.
2. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009, 119:1211-1219. 10.1161/CIRCULATIONAHA.108.814947, 2730832, 19237658.
3. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG, Steingart R, Picard MH, Menegus MA, Boland J, Sanborn T, Buller CE, Modur S, Forman R, Desvigne-Nickens P, Jacobs AK, Slater JN, LeJemtel TH. SHOCK Investigators: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock: one-year survival following early revascularization for cardiogenic shock. JAMA 2001, 285:190-192. 10.1001/jama.285.2.190, 11176812.
4. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD, . for the SHOCK Investigators Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006, 295:2511-2515. 10.1001/jama.295.21.2511, 1782030, 16757723, for the SHOCK Investigators.
5. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008, 117:686-697. 10.1161/CIRCULATIONAHA.106.613596, 18250279.
6. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, . Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167. 10.1056/NEJMoa020233, 12124404, Breathing Not Properly Multinational Study Investigators.
7. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD, . Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004, 110:3206-3212. 10.1161/01.CIR.0000147611.92021.2B, 15533869, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators.
8. Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006, 34:2140-2144. 10.1097/01.CCM.0000229144.97624.90, 16763507.
9. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005, 165:1643-1650. 10.1001/archinte.165.14.1643, 16043684.
10. Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, Siostrzonek P, Huber K, Heinz G. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002, 30:1987-1994. 10.1097/00003246-200209000-00007, 12352031.
11. Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006, 34:2035-2042. 10.1097/01.CCM.0000228919.33620.D9, 16775569.
12. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008, 36:941-952. 10.1097/CCM.0B013E318165BABB, 18431284.
13. Bektas F, Soyuncu S, Gunduz I, Basarici I, Akbas H, Eken C. The value of procalcitonin, a novel inflammatory marker, in the diagnosis of myocardial infarction and evaluation of acute coronary syndrome patients. J Emerg Med 2011, 41:524-530. 10.1016/j.jemermed.2010.05.073, 20813483.
14. Kafkas N, Venetsanou K, Patsilinakos S, Voudris V, Antonatos D, Kelesidis K, Baltopoulos G, Maniatis P, Cokkinos DV. Procalcitonin in acute myocardial infarction. Acute Card Care 2008, 10:30-36. 10.1080/17482940701534800, 17924232.
15. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeLemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999, 341:625-634. 10.1056/NEJM199908263410901, 10460813.
16. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, Gibson CM, Antman EM, Braunwald E. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004, 44:335-339. 10.1016/j.jacc.2004.04.033, 15261928.
17. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Nekolla S, Vogt W, Schwaiger M, Schömig A, Kastrati A. N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. Am J Cardiol 2006, 97:1151-1156. 10.1016/j.amjcard.2005.11.029, 16616017.
18. Vergès B, Zeller M, Desgrès J, Dentan G, Laurent Y, Janin-Manificat L, L'Huillier I, Rioufol G, Beer JC, Makki H, Rochette L, Gambert P, Cottin Y. High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock. Eur Heart J 2005, 26:1734-1741. 10.1093/eurheartj/ehi260, 15831555.
19. Jarai R, Fellner B, Haoula D, Jordanova N, Heinz G, Karth GD, Huber K, Geppert A. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med 2009, 37:1837-1844. 10.1097/CCM.0b013e31819fe896, 19384228.
20. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 1993, 103:565-575. 10.1378/chest.103.2.565, 8432155.
21. Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005, 26:1964-1970. 10.1093/eurheartj/ehi292, 15872036.
22. Shpektor A. Cardiogenic shock: the role of inflammation. Acute Card Care 2010, 12:115-118. 10.3109/17482941.2010.523705, 21039083.
23. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389. 10.1126/science.1631560, 1631560.
24. Sinning CR, Sinning JM, Schulz A, Schnabel RB, Lubos E, Wild PS, Papassotiriou J, Bergmann A, Blankenberg S, Munzel T, Bickel C, . AtheroGene Study Investigators Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 2011, 75:1184-1191. 10.1253/circj.CJ-10-0638, 21378450, AtheroGene Study Investigators.
25. Geppert A, Steiner A, Delle-Karth G, Heinz G, Huber K. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 2003, 29:1384-1389. 10.1007/s00134-003-1827-7, 12827235.
26. Picariello C, Lazzeri C, Chiostri M, Gensini G, Valente S. Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Int Emerg Med 2009, 4:403-408.
27. Hasdai D, Holmes DR, Califf RM, Thompson TD, Hochman JS, Pfisterer M, Topol EJ. Cardiogenic shock complicating acute myocardial infarction: predictors of death. Am Heart J 1999, 138:21-31. 10.1016/S0002-8703(99)70241-3, 10385759.
28. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeLemtel TH, Cotter G. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry: SHOCK Investigators. J Am Coll Cardiol 2004, 44:340-348. 10.1016/j.jacc.2004.03.060, 15261929.
29. Koreny M, Karth GD, Geppert A, Neunteufl T, Priglinger U, Heinz G, Siostrzonek P. Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002, 112:115-119. 10.1016/S0002-9343(01)01070-1, 11835949.
30. Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, Moltrasio M, Rubino M, Veglia F, Montorsi P, Bartorelli AL. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010, 38:438-444. 10.1097/CCM.0b013e3181b9eb3b, 19789449.